Boris Fehse (B Fehse)

Scopus Author ID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 48

Top Venues

Leukemia

Cancers

Nature communications

Gene therapy

Universitätsklinikum Hamburg-Eppendorf

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universitätsklinikum Hamburg-Eppendorf Jan 01 2009

Germany

Head :: Research Dept. Cell & Gene Therapy, Dept. of SCT

Publications

Fabian Bernhard Pallasch, Vera Freytag, Malte Kriegs, Dennis Gatzemeier, Thomas Mair, Hannah Voss, Kristoffer Riecken, Mona Dawood, Boris Fehse, Thomas Efferth, Hartmut Schlüter, Udo Schumacher
The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System. Cancers 16 (12) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Maraike Harfmann, Tanja Schröder, Dawid Głów, Maximilian Jung, Almut Uhde, Nicolaus Kröger, Stefan Horn, Kristoffer Riecken, Boris Fehse, Francis A Ayuk
CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture. Cancers 16 (2) (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia 38 (2) (2024)
Leon U B Enk, Malte Hellmig, Kristoffer Riecken, Christoph Kilian, Paul Datlinger, Saskia L Jauch-Speer, Tobias Neben, Zeba Sultana, Amirrtavarshni Sivayoganathan, Alina Borchers, Hans-Joachim Paust, Yu Zhao, Nariaki Asada, Shuya Liu, Theodora Agalioti, Penelope Pelczar, Thorsten Wiech, Christoph Bock, Tobias B Huber, Samuel Huber, Stefan Bonn, Nicola Gagliani, Boris Fehse, Ulf Panzer, Christian F Krebs
Targeting T cell plasticity in kidney and gut inflammation by pooled single-cell CRISPR screening. Science immunology 9 (96) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia 38 (2) (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia 38 (2) (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia 38 (2) (2024)
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis Ayuk, Boris Fehse, Ulrike Bacher, Nicolaus Kröger
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia 38 (2) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Wolfgang W Schamel, Marina Zinchenko, Trang Nguyen, Boris Fehse, Priscilla S Briquez, Susana Minguet
The potential of γδ CAR and TRuC T cells: An unearthed treasure. European journal of immunology (2024)
Fabian Bernhard Pallasch, Vera Freytag, Malte Kriegs, Dennis Gatzemeier, Thomas Mair, Hannah Voss, Kristoffer Riecken, Mona Dawood, Boris Fehse, Thomas Efferth, Hartmut Schlüter, Udo Schumacher
The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System. Cancers 16 (12) (2024)
Maraike Harfmann, Tanja Schröder, Dawid Głów, Maximilian Jung, Almut Uhde, Nicolaus Kröger, Stefan Horn, Kristoffer Riecken, Boris Fehse, Francis A Ayuk
CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture. Cancers 16 (2) (2024)
Max Wichmann, Cecile L Maire, Niklas Nuppenau, Moataz Habiballa, Almut Uhde, Katharina Kolbe, Tanja Schröder, Katrin Lamszus, Boris Fehse, Dawid Głów
Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs. International journal of molecular sciences 24 (14) (2023)
Lisa Staffeldt, Gregor Mattert, Kristoffer Riecken, Götz Rövenstrunk, Anika Volkmar, Asmus Heumann, Mohamed Moustafa, Manfred Jücker, Boris Fehse, Udo Schumacher, Stefan Lüth, Janine Kah
Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation. Cells 13 (1) (2023)
Lisa Staffeldt, Gregor Mattert, Kristoffer Riecken, Götz Rövenstrunk, Anika Volkmar, Asmus Heumann, Mohamed Moustafa, Manfred Jücker, Boris Fehse, Udo Schumacher, Stefan Lüth, Janine Kah
Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation. Cells 13 (1) (2023)
Lisa Staffeldt, Gregor Mattert, Kristoffer Riecken, Götz Rövenstrunk, Anika Volkmar, Asmus Heumann, Mohamed Moustafa, Manfred Jücker, Boris Fehse, Udo Schumacher, Stefan Lüth, Janine Kah
Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation. Cells 13 (1) (2023)
Lisa Staffeldt, Gregor Mattert, Kristoffer Riecken, Götz Rövenstrunk, Anika Volkmar, Asmus Heumann, Mohamed Moustafa, Manfred Jücker, Boris Fehse, Udo Schumacher, Stefan Lüth, Janine Kah
Generating Patient-Derived HCC Cell Lines Suitable for Predictive In Vitro and In Vivo Drug Screening by Orthotopic Transplantation. Cells 13 (1) (2023)
Marlene Luther, Frank Oliver Henes, Tatjana Zabelina, Radwan Massoud, Dietlinde Janson, Christine Wolschke, Evgeny Klyuchnikov, Nico Gagelmann, Boris Fehse, Gerhard Adam, Nicolaus Kröger, Francis A Ayuk
Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone marrow transplantation (2023)
Britta Franziska Zecher, David Ellinghaus, Sebastian Schloer, Annika Niehrs, Benedetta Padoan, Martin E Baumdick, Yuko Yuki, Maureen P Martin, Dawid Glow, Jennifer Schröder-Schwarz, Jennifer Niersch, Sébastien Brias, Luisa M Müller, Robin Habermann, Paul Kretschmer, Tristan Früh, Janis Dänekas, Malte H Wehmeyer, Tobias Poch, Marcial Sebode, null null, Eva Ellinghaus, Frauke Degenhardt, Christian Körner, Angelique Hoelzemer, Boris Fehse, Karl J Oldhafer, Udo Schumacher, Guido Sauter, Mary Carrington, Andre Franke, Madeleine J Bunders, Schramm Christoph, Marcus Altfeld
HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. Gut (2023)
Frauke Gotzhein, Tim Aranyossy, Lars Thielecke, Tanja Sonntag, Vanessa Thaden, Boris Fehse, Ingo Müller, Ingmar Glauche, Kerstin Cornils
The Reconstitution Dynamics of Cultivated Hematopoietic Stem Cells and Progenitors Is Independent of Age. International journal of molecular sciences 23 (6) (2022)
Mohamed Moustafa, Katarzyna-Krystyna Dähling, Armin Günther, Leonie Riebandt, Daniel J Smit, Kristoffer Riecken, Carina Schröder, Ruimeng Zhuang, Till Krech, Malte Kriegs, Boris Fehse, Jakob R Izbicki, Lutz Fischer, Björn Nashan, Jun Li, Manfred Jücker
Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM + and CD90 + Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers 14 (8) (2022)
Kerri Hagemann, Kristoffer Riecken, Johannes M Jung, Heike Hildebrandt, Stephan Menzel, Madeleine J Bunders, Boris Fehse, Friedrich Nolte, Fabian Heinrich, Sven Peine, Julian Schulze Zur Wiesch, Thomas T Brehm, Marylyn M Addo, Marc Lütgehetmann, Marcus Altfeld
Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. European journal of immunology 52 (8) (2022)
Lea Isabell Schwarze, Dawid Głów, Tanja Sonntag, Almut Uhde, Boris Fehse
Correction: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene therapy (2022)
Daniele Mannina, Anita Badbaran, Christine Wolschke, Evgeny Klyuchnikov, Maximilian Christopeit, Boris Fehse, Nicolaus Kröger
Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. Bone marrow transplantation 57 (3) (2022)
Lena-Marie Martin, Anne Kruchen, Boris Fehse, Ingo Müller
Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts. Biomedicines 10 (3) (2022)
Adrin Dadkhah, Sebastian Georg Wicha, Nicolaus Kröger, Alexander Müller, Christoph Pfaffendorf, Maria Riedner, Anita Badbaran, Boris Fehse, Claudia Langebrake
Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation. Pharmaceutics 14 (6) (2022)
Dawid Głów, Cecile L Maire, Lea Isabell Schwarze, Katrin Lamszus, Boris Fehse
CRISPR-to-Kill (C2K)-Employing the Bacterial Immune System to Kill Cancer Cells. Cancers 13 (24) (2021)
Lea Isabell Schwarze, Tanja Sonntag, Stefan Wild, Sabrina Schmitz, Almut Uhde, Boris Fehse
Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients. Gene therapy 28 (9) (2021)
Lea Isabell Schwarze, Dawid Głów, Tanja Sonntag, Almut Uhde, Boris Fehse
Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene therapy 28 (9) (2021)
Manuela Mirow, Lea Isabell Schwarze, Boris Fehse, Kristoffer Riecken
Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope. Viruses 13 (8) (2021)
Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Eva Hoster, Carolina Susanna Berger, Liv Jentzsch, Dimitrios Mougiakakos, Lisa Frölich, Josephine Ackermann, Veit L Bücklein, Viktoria Blumenberg, Christian Schmidt, Laurent Jallades, Boris Fehse, Christoph Faul, Philipp Karschnia, Oliver Weigert, Martin Dreyling, Frederick L Locke, Michael von Bergwelt-Baildon, Andreas Mackensen, Wolfgang Andreas Bethge, Francis Ayuk, Emmanuel Bachy, Gilles Andre Salles, Michael D Jain, Marion Subklewe
CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood (2021)
Ina Annelies Stelzer, Christopher Urbschat, Steven Schepanski, Kristin Thiele, Ioanna Triviai, Agnes Wieczorek, Malik Alawi, Denise Ohnezeit, Julian Kottlau, Jiabin Huang, Nicole Fischer, Hans-Willi Mittrücker, Maria Emilia Solano, Boris Fehse, Anke Diemert, Felix R Stahl, Petra Clara Arck
Vertically transferred maternal immune cells promote neonatal immunity against early life infections. Nature communications 12 (1) (2021)
Michael A Morgan, Melanie Galla, Manuel Grez, Boris Fehse, Axel Schambach
Retroviral gene therapy in Germany with a view on previous experience and future perspectives. Gene therapy 28 (9) (2021)
Francis A Ayuk, Carolina Berger, Anita Badbaran, Tatjana Zabelina, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Dominic Wichmann, Christian Frenzel, Guenther Thayssen, Silke Zeschke, Nicolaus M Kröger, Boris Fehse
Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood advances 5 (11) (2021)
Kristoffer Riecken, Dawid Głów, Boris Fehse
How to package and SEND mRNA: a novel "humanized" vector system based on endogenous retroviruses. Signal transduction and targeted therapy 6 (1) (2021)
Michela Carlet, Kerstin Völse, Jenny Vergalli, Martin Becker, Tobias Herold, Anja Arner, Daniela Senft, Vindi Jurinovic, Wen-Hsin Liu, Yuqiao Gao, Veronika Dill, Boris Fehse, Claudia D Baldus, Lorenz Bastian, Lennart Lenk, Denis Martin Schewe, Johannes W Bagnoli, Binje Vick, Jan Philipp Schmid, Alexander Wilhelm, Rolf Marschalek, Philipp J Jost, Christoph Cornelius Miething, Kristoffer Riecken, Marc Schmidt-Supprian, Vera Binder, Irmela Jeremias
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. Nature communications 12 (1) (2021)
Nico Gagelmann, Kristoffer Riecken, Christine Wolschke, Carolina Berger, Francis A Ayuk, Boris Fehse, Nicolaus Kröger
Development of CAR-T cell therapies for multiple myeloma. Leukemia 34 (9) (2020)
Lisa von Wenserski, Christoph Schultheiß, Sarah Bolz, Simon Schliffke, Donjete Simnica, Edith Willscher, Helwe Gerull, Gerrit Wolters-Eisfeld, Kristoffer Riecken, Boris Fehse, Marcus Altfeld, Peter Nollau, Mascha Binder
SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. Leukemia 35 (4) (2020)
Simon Dulz, Mahmoud Bassal, Kai Flachsbarth, Kristoffer Riecken, Boris Fehse, Stefanie Schlichting, Susanne Bartsch, Udo Bartsch
Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal Ganglion Cells in Mice. Cells 9 (9) (2020)
Anita Badbaran, Carolina Berger, Kristoffer Riecken, Anne Kruchen, Maria Geffken, Ingo Müller, Nicolaus Kröger, Francis A Ayuk, Boris Fehse
Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. Cancers 12 (7) (2020)
Bernhard Ellinger, Daniel Pohlmann, Jannis Woens, Felix M Jäkel, Jeanette Reinshagen, Carol Stocking, Vladimir S Prassolov, Boris Fehse, Kristoffer Riecken
A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1. Viruses 12 (5) (2020)
Joseph Tintelnot, Natalie Baum, Christoph Schultheiß, Friederike Braig, Marie Trentmann, Johannes Finter, William Fumey, Peter Bannas, Boris Fehse, Kristoffer Riecken, Kerstin Schuetze, Carsten Bokemeyer, Thies Rösner, Thomas Valerius, Matthias Peipp, Friedrich Koch-Nolte, Mascha Binder
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. Molecular cancer therapeutics 18 (4) (2019)
M Täger, S Horn, E Latuske, P Ehm, M Schaks, M Nalaskowski, Boris Fehse, W Fiedler, C Stocking, J Wellbrock, M Jücker
SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model. Gene therapy 24 (11) (2017)
Ulrike Mock, Ilona Hauber, Boris Fehse
Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases. Nature protocols 11 (3) (2016)
A Badbaran, Boris Fehse, M Christopeit, T Aranyossy, F A Ayuk, C Wolschke, N Kröger
Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone marrow transplantation 51 (6) (2016)

Boris Fehse.css-eqlu8i{font-size:small;padding-left:4px;} (B Fehse)

Publication Activity (10 Years)

Top Topics

Top Venues

Boris Fehse (B Fehse)